How does one choose the appropriate pharmacotherapy for children with lower respiratory tract infections?
Susanna Esposito1, Sonia Bianchini1, Alberto Argentiero1
1Pediatric Clinic, Pietro Barilla Children's Hospital, Department of Medicine and Surgery, University of Parma , Parma, Italy.
Insights
Anti-infective therapy for pediatric acute lower respiratory tract infections (LRTIs) remains challenging. Despite advances, current treatments for conditions like pneumonia and bronchiolitis are often unsatisfactory, necessitating further research and improved drug strategies.
Area of Science:
- Pediatric infectious diseases
- Pharmacology
- Respiratory medicine
Background:
- Acute lower respiratory tract infections (LRTIs) are common in children, encompassing conditions like community-acquired pneumonia (CAP), bronchiolitis (BCL), bronchitis (BR), and tuberculosis (TB).
- Effective anti-infective therapy is crucial for managing pediatric LRTIs, which are significant causes of hospitalization and mortality.
- Antibiotics and antivirals are key therapeutic agents for these infections.
Purpose of the Study:
- To review recent advancements in the drug treatment of LRTIs in children.
- To highlight current challenges and unmet needs in pediatric LRTI pharmacotherapy.
Main Methods:
- Literature review of recent advances in drug treatment for pediatric LRTIs.
- Discussion of therapeutic strategies for specific conditions including CAP, BR, BCL, and TB.
Main Results:
- Anti-infective therapy for pediatric LRTIs is currently unsatisfactory.
- Overuse and misuse of antibiotics are significant issues in treating CAP and BR.
- Lack of effective, safe, and well-tolerated drugs is a problem for BCL treatment.
Conclusions:
- Significant challenges persist in the drug treatment of pediatric LRTIs.
- Further research is needed to develop more effective and safer anti-infective therapies.
- Addressing antibiotic misuse and developing novel treatments are critical for improving outcomes in pediatric respiratory infections.
Introduction:
The definition of acute lower respiratory tract infection (LRTI) includes any infection involving the respiratory tract below the level of the larynx. In children, the most common acute LRTIs, and those with the greatest clinical relevance, are community-acquired pneumonia (CAP), bronchiolitis, bronchitis and tuberculosis (TB). The clinical relevance of LRTIs implies that they must be addressed with the most effective therapy. Antibiotics and antivirals play an essential role in this regard.
Areas Covered:
In this paper, the most recent advances in the drug treatment of LRTIs in children are discussed.
Expert Opinion:
Although LRTIs are extremely common and one of the most important causes of hospitalization and death in children, anti-infective therapy for these diseases remains unsatisfactory. For CAP and BR, the most important problem is the overuse and misuse of antibiotics; for BCL, the lack of drugs with demonstrated efficacy, safety and tolerability; for TB, the poor knowledge on the true efficacy and safety of the new drugs specifically planned to overcome the problem of MDR M. tuberculosis strains. There is still a long way to go for the therapy of pediatric LRTIs to be considered satisfactory.
Related Concept Videos
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:23Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
01:16Drugs Used in Upper Respiratory Disorders: Overview
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption